Inclusion Criteria:

          -  ELIGIBILITY FOR ENROLLMENT

          -  Histopathologic documentation of melanoma concurrent with the diagnosis of metastatic
             disease

          -  Expression of human leukocyte antigen (HLA)-A2

          -  Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of '0-1' at
             screening visit

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study in such a manner that the risk
             of pregnancy is minimized; suggested precautions should be used to minimize the risk
             of pregnancy for at least 1 month before start of therapy, and while women are on
             study for up to 3 months after T cell infusion, and at least 8 weeks after the study
             drug is stopped; WOCBP include any female who has experienced menarche and who has not
             undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or
             bilateral oophorectomy) or is not postmenopausal

          -  Men must be willing and able to use an acceptable method of birth control, for at
             least 3 months after completion of the study, if their sexual partners are WOCBP

          -  Willing and able to give informed consent

          -  Adequate venous access - consider peripherally inserted central catheter (PICC) or
             central line

          -  Evaluation of v-raf murine sarcoma viral oncogene homolog B (BRAF)V600 mutation status

          -  Measurable tumor (by Response Evaluation Criteria in Solid Tumors [RECIST] criteria)

          -  Melan-A (MART) 1 or solute carrier family 45, member 2 (SLC45A2) (+) staining results;
             (if patients have not had staining test in the past, the test will be run after
             patient consent is obtained, but before enrollment)

          -  ELIGIBILITY FOR TREATMENT (INCLUDES CYCLOPHOSPHAMIDE, T CELL, ANTI-CTLA4 INFUSIONS AND
             SC IL-2)

          -  ECOG/Zubrod performance status of '0-1'

          -  At least 4 weeks must have elapsed since the last chemotherapy, radiotherapy or major
             surgery; at least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin; if
             started before T-cell administration, ipilimumab infusions must be least 21 days apart

          -  Toxicity related to prior therapy must either have returned to =< grade 1, baseline,
             or been deemed irreversible

          -  Persons of reproductive potential must agree to use and utilize an adequate method of
             contraception throughout treatment and for at least 8 weeks after study drug is
             stopped

          -  Willing and able to give informed consent.

        Exclusion Criteria:

          -  EXCLUSION FOR ENROLLMENT

          -  Any other malignancy from which the patient has been disease-free for less than 5
             years, with the exception of adequately treated and cured basal or squamous cell skin
             cancer, superficial bladder cancer, carcinoma in situ of the cervix

          -  Pregnant women, nursing mothers, men or women of reproductive ability who are
             unwilling to use effective contraception; women of childbearing potential with a
             positive pregnancy test within 3 days prior to entry

          -  Active and untreated central nervous system (CNS) metastasis (including metastasis
             identified during screening magnetic resonance imaging [MRI] or contrast computed
             tomography [CT])

          -  No signs or symptoms of CNS metastases (mets) within the last 30 days (from enrollment
             evaluation)

          -  No single lesion larger than 1 cm

          -  No more than 5 lesions

          -  Autoimmune disease: patients with a history of inflammatory bowel disease are excluded
             from this study, as are patients with a history of autoimmune disease (e.g. systemic
             lupus erythematosus, vasculitis, infiltrating lung disease) whose possible progression
             during treatment would be considered by the investigator to be unacceptable

          -  Any underlying medical or psychiatric condition, which in the opinion of the
             investigator, will make the administration of study drug hazardous or obscure the
             interpretation of adverse events, such as a condition associated with frequent
             diarrhea

          -  Positive screening tests for human immunodeficiency virus (HIV), hepatitis B (hep B),
             and hepatitis C (hep C) (referencing blood draw at leukapheresis screening); if
             positive results are not indicative of true active or chronic infection, the patient
             can be treated

          -  White blood cells (WBC) =< 1000/uL

          -  Hematocrit (Hct) =< 24% or hemoglobin (Hb) =< 8 g/dL

          -  Absolute neutrophil count (ANC) =< 500

          -  Platelets =< 50,000

          -  Creatinine >= 3.0 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >= 2.5 x ULN

          -  Bilirubin >= 3 x ULN

          -  Steroids are not permitted 3 days prior to T cell infusion and concurrently during
             therapy

          -  Any non-oncology vaccine therapy used for the prevention of infectious disease within
             1 month before or after any ipilimumab dose

          -  Patients may not be on any other treatments for their cancer aside from those included
             in the protocol; patients may not undergo another form of treatment concurrently with
             this study

          -  EXCLUSION CRITERIA FOR TREATMENT

          -  WBC =< 1000/uL (prior to cyclophosphamide and T cell infusions)

          -  Hct =< 24% or hemoglobin =< 8 g/dL (prior to cyclophosphamide and T cell infusions)

          -  ANC =< 500 (prior to cyclophosphamide and T cell infusions)

          -  Platelets =< 50,000 (prior to cyclophosphamide and T cell infusions)

          -  Creatinine >= 3.0 x ULN (prior to cyclophosphamide and T cell infusions)

          -  AST/ALT >= 2.5 x ULN (prior to cyclophosphamide and T cell infusions)

          -  Bilirubin >= 3 x ULN (prior to cyclophosphamide and T cell infusions)

          -  Pregnant women, nursing mothers, men or women of reproductive ability who are
             unwilling to use effective contraception; women of childbearing potential with a
             positive pregnancy test within 3 days prior to entry.

          -  Steroids are not permitted 3 days prior to T cell infusion and concurrently during
             therapy.

          -  Any non-oncology vaccine therapy used for the prevention of infectious disease within
             1 month before or after any ipilimumab dose.

          -  Patients may not be on any other treatments for their cancer aside from those included
             in the protocol. Patients may not undergo another form of treatment concurrently with
             this study.

          -  Active and untreated central nervous system (CNS) metastasis (including metastasis
             identified during screening MRI or contrast CT):

               -  No signs or symptoms of CNS mets within the last 30 days (from enrollment
                  evaluation).

               -  No single lesion larger than 1cm

               -  No more than 5 lesions